Ratings Yuhan Corporation

Equities

A000100

KR7000100008

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
73,200 ^KRW	+2.23%		+4.87%	+6.40%

Mar. 07	Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 08	Progen Co., Ltd. announced that it has received KRW 9.71405799 billion in funding from Yuhan Corporation and other investors	CI

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company is in a robust financial situation considering its net cash and margin position.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
With an expected P/E ratio at 35.22 and 27.69 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
YUHAN CORPORATION	+6.40%	3.87B		B-
KYOWA KIRIN CO. LTD.	+12.28%	9.18B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.78B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+26.98%	3.73B		-
INDIVIOR PLC	+28.27%	2.52B		B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.55%	2.27B		-
BETTA PHARMACEUTICALS CO., LTD.	-25.02%	2.21B		C-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+5.82%	1.95B	-	-
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B	-	-
SUPERNUS PHARMACEUTICALS, INC.	+3.49%	1.63B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes